Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

Cancer Res (2024) 84 (9_Supplement): GS03-03.

https://doi.org/10.1158/1538-7445.SABCS23-GS03-03

Published: 02 May 2024

View articletitled, Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

Journal Articles

Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer

Fatima Cardoso, William Jacot, Sherko Küemmel, Sudeep Gupta, Rama Balaraman, Liudmila Lebedeva, Yan Ji, Aparna Lakshmanan, Khalid Amin, Zheng Li, Joseph Sparano

Cancer Res (2023) 83 (5_Supplement): PD17-12.

https://doi.org/10.1158/1538-7445.SABCS22-PD17-12

Published: 01 March 2023

View articletitled, Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer

Journal Articles

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Feiteng Huang, Jie Sun, Wei Chen, Lei Zhang, Xin He, Haojie Dong, Yuhui Wu, Hanying Wang, Zheng Li, Victor Huang, Samer Khaled, Ling Li

Cancer Res (2021) 81 (13_Supplement): 2934.

https://doi.org/10.1158/1538-7445.AM2021-2934

Published: 01 July 2021

View articletitled, Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Journal Articles

Abstract 2252: Significant impacts of IMRT on peripheral blood lymphocyte subpopulation and immune globulin levels in head and neck cancer patients

Qiuji WU, Shuyuan Zhang, Zheng LI, Yahua Zhong

Cancer Res (2020) 80 (16_Supplement): 2252.

https://doi.org/10.1158/1538-7445.AM2020-2252

Published: 15 August 2020

View articletitled, Abstract 2252: Significant impacts of IMRT on peripheral blood lymphocyte subpopulation and immune globulin levels in head and neck cancer patients

Journal Articles

Abstract 3394: Diagnosis of intrahepatic metastasis (IM) and multi-entric (MC) carcinogenesis by novel mutational signature in patients with multiple and recurrent hepatocellular carcinomas

Pinghua Yang, Shilei Bai, Yanpeng Zhang, Zhihao Xie, Zhangjun Cheng, Jie Yang, Jun Li, Jiaqian Wang, Zhengqing Lei, Yong Xia, Kui Wang, Zheng Li, Baohua Zhang, Xuying Wan, Mengchao Wu, Feng Shen

Cancer Res (2019) 79 (13_Supplement): 3394.

https://doi.org/10.1158/1538-7445.AM2019-3394

Published: 01 July 2019

View articletitled, Abstract 3394: Diagnosis of intrahepatic metastasis (IM) and multi-entric (MC) carcinogenesis by novel mutational signature in patients with multiple and recurrent hepatocellular carcinomas

Journal Articles

Abstract 2236: Development and validation of urine cfDNA preservative kit for detection of genomic alterations in cancer

Zheng Li, Haoran Tang, Tiantian Zhang, Chunxiao Liu, Shengnan Zhu, Ying Zhang, Binggang Xiang, Zhixin Zhao

Cancer Res (2019) 79 (13_Supplement): 2236.

https://doi.org/10.1158/1538-7445.AM2019-2236

Published: 01 July 2019

View articletitled, Abstract 2236: Development and validation of urine cfDNA preservative kit for detection of genomic alterations in cancer

Journal Articles

Abstract 1259: Loss of TFF1 promotes growth and chemotherapeutic resistance in gastric cancer

Zheng Chen, Zheng Li, Mohammed Soutto, Weizhi Wang, Shoumin Zhu, Alejandro Corvalan, Zekuan Xu, Wael El-Rifai

Cancer Res (2018) 78 (13_Supplement): 1259.

https://doi.org/10.1158/1538-7445.AM2018-1259

Published: 01 July 2018

View articletitled, Abstract 1259: Loss of TFF1 promotes growth and chemotherapeutic resistance in gastric cancer

Journal Articles

Abstract LB-019: Empowering preclinical studies: A systematic and quantitative analysis of biodistribution methods to facilitate clinical translation of new drugs

Sara Nizzero, Feng Li, Alessandro Venuta, Guodong Zhang, Carlotta Borsoi, Joy Wolfram, Junhua Mai, Haifa Shen, Zheng Li, Elvin Blanco, Mauro Ferrari

Cancer Res (2018) 78 (13_Supplement): LB-019.

https://doi.org/10.1158/1538-7445.AM2018-LB-019

Published: 01 July 2018

View articletitled, Abstract LB-019: Empowering preclinical studies: A systematic and quantitative analysis of biodistribution methods to facilitate clinical translation of new drugs

Journal Articles

Abstract 2312: Identifying novel cancer stem cell target for triple-negative breast cancer

Yi Liu, Dong Soon Choi, Sergio Grandos-Principal, Wei Qian, Lacey Burey, Helen Wong, Crisitian Rodriguez-Aguayo, Anil Sood, Zheng Li, Stephen Wong, Heidi Weiss, Bhuvanesh Dave, Melissa Landis, Jenny C. Chang

Cancer Res (2015) 75 (15_Supplement): 2312.

https://doi.org/10.1158/1538-7445.AM2015-2312

Published: 01 August 2015

View articletitled, Abstract 2312: Identifying novel cancer stem cell target for triple-negative breast cancer

Journal Articles

Abstract 5171: FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes p53-dependent checkpoint response.

Zheng Li, Shuangshuang Yan, Li Qiu, Jun Zhang, Ke Ma, Xifeng Zhang, Xishan Hao

Cancer Res (2013) 73 (8_Supplement): 5171.

https://doi.org/10.1158/1538-7445.AM2013-5171

Published: 15 April 2013

View articletitled, Abstract 5171: FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes p53-dependent checkpoint response.

Journal Articles

Abstract 3859: Multivalency of non-peptide integrin α_Vβ₃ antagonist slows tumor growth

Yoo-Shin Kim, Feng Li, Brian E. O'neill, King CP Li, Zheng Li

Cancer Res (2012) 72 (8_Supplement): 3859.

https://doi.org/10.1158/1538-7445.AM2012-3859

Published: 15 April 2012

View articletitled, Abstract 3859: Multivalency of non-peptide integrin αVβ3 antagonist slows tumor growth

Journal Articles

Abstract 2339: Specific binding of modified ZD 6474 (Vandetanib) monomer and its dimer with VEGF receptor 2

Yoo-Shin Kim, Feng Li, Brian Edward O'neill, King CP Li, Zheng Li

Cancer Res (2012) 72 (8_Supplement): 2339.

https://doi.org/10.1158/1538-7445.AM2012-2339

Published: 15 April 2012

View articletitled, Abstract 2339: Specific binding of modified ZD 6474 (Vandetanib) monomer and its dimer with VEGF receptor 2

Journal Articles

Abstract 254: A HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis

Zheng Li, Qian Zhang, Jian-Hua Mao, Anja Weise, Kristin Mrasek, Xueyu Fan, Xifeng Zhang, Thomas Liehr, Karen H. Lu, Allan Balmain, Wei-Wen Cai

Cancer Res (2010) 70 (8_Supplement): 254.

https://doi.org/10.1158/1538-7445.AM10-254

Published: 15 April 2010

View articletitled, Abstract 254: A HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis

Journal Articles

Abstract #LB-105: Identification of FATS as a fragile site gene involved in DNA damage signaling and tumorigenesis.

Zheng Li, Wei-Wen Cai

Cancer Res (2009) 69 (9_Supplement): LB-105.

Published: 01 May 2009

View articletitled, Abstract #LB-105: Identification of FATS as a fragile site gene involved in DNA damage signaling and tumorigenesis.

Journal Articles

GeMAC, an HDAC1 binding protein, stabilizes p21 and co-activates p53 in response to DNA damage

Zheng Li, Wei-Wen Cai

Cancer Res (2007) 67 (9_Supplement): 4926.

Published: 01 May 2007

View articletitled, GeMAC, an HDAC1 binding protein, stabilizes p21 and co-activates p53 in response to DNA damage

Journal Articles

Suppression of pancreatic ttmor progression by systemic delivery of a pancreatic-cancer-specific promoter driven bik mutant

Zheng Li, Qingqing Ding, Yan Li, Mien-Chie Hung

Cancer Res (2006) 66 (8_Supplement): 494.

Published: 15 April 2006

View articletitled, Suppression of pancreatic ttmor progression by systemic delivery of a pancreatic-cancer-specific promoter driven bik mutant

Journal Articles

Identification of GeMAC as a tumor suppressor required for genomic stability

Zheng Li, Qian Zhang, Jian-Hua Mao, Linus Ho, Allan Balmain, Wei-Wen Cai

Cancer Res (2006) 66 (8_Supplement): 765.

Published: 15 April 2006

View articletitled, Identification of GeMAC as a tumor suppressor required for genomic stability

Journal Articles

Identification of a novel methylation marker, SCNN1B

Jeanne P. Harvey, Allison Gannon, Zheng Li, Chris Beard, Chris Burgess

Cancer Res (2005) 65 (9_Supplement): 217–218.

Published: 01 May 2005

View articletitled, Identification of a novel methylation marker, SCNN1B

Journal Articles

Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin

Qingqing Ding, Weiya Xia, Jaw-Ching Liu, Jer-Yen Yang, Jiahong Xia, Dung-Fang Lee, Geoffrey Bartholomeusz, Yan Li, Yong Pan, Zheng Li, Jun Qin, Mien-Chie Hung

Cancer Res (2005) 65 (9_Supplement): 238.

Published: 01 May 2005

View articletitled, Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin

Journal Articles

Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53

Zheng Li, Chi-Ping Day, Jer-Yen Yang, Wen-Bin Tsai, Guillermina Lozano, Hsiu-Ming Shih, Mien-Chie Hung

Cancer Res (2004) 64 (24): 9080–9085.

https://doi.org/10.1158/0008-5472.CAN-04-2419

Published: 16 December 2004

View articletitled, Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Abstract 2252: Significant impacts of IMRT on peripheral blood lymphocyte subpopulation and immune globulin levels in head and neck cancer patients

Abstract 3394: Diagnosis of intrahepatic metastasis (IM) and multi-entric (MC) carcinogenesis by novel mutational signature in patients with multiple and recurrent hepatocellular carcinomas

Abstract 2236: Development and validation of urine cfDNA preservative kit for detection of genomic alterations in cancer

Abstract 1259: Loss of TFF1 promotes growth and chemotherapeutic resistance in gastric cancer

Abstract LB-019: Empowering preclinical studies: A systematic and quantitative analysis of biodistribution methods to facilitate clinical translation of new drugs

Abstract 2312: Identifying novel cancer stem cell target for triple-negative breast cancer

Abstract 5171: FATS is an E2-independent ubiquitin ligase that stabilizes p53 and promotes p53-dependent checkpoint response.

Abstract 3859: Multivalency of non-peptide integrin α_Vβ₃ antagonist slows tumor growth

Abstract 2339: Specific binding of modified ZD 6474 (Vandetanib) monomer and its dimer with VEGF receptor 2

Abstract 254: A HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis

Abstract #LB-105: Identification of FATS as a fragile site gene involved in DNA damage signaling and tumorigenesis.

GeMAC, an HDAC1 binding protein, stabilizes p21 and co-activates p53 in response to DNA damage

Suppression of pancreatic ttmor progression by systemic delivery of a pancreatic-cancer-specific promoter driven bik mutant

Identification of GeMAC as a tumor suppressor required for genomic stability

Identification of a novel methylation marker, SCNN1B

Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin

Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only